Kymab, Heptares Enter GPCR Targeting Pact
This article was originally published in Scrip
Executive Summary
Two of Britain's leading science innovators – Mab specialist Kymab Ltd. and GPCR-targeting Heptares Therapeutics – are joining forces to discover, develop and commercialize new antibody drugs targeting a number of G protein-coupled receptors, focusing initially on immuno-oncology.
You may also be interested in...
Heptares-Powered Sosei's Incoming CEO Explains What Happens Next
Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.